Mineralys Therapeutics Past Earnings Performance
Past criteria checks 0/6
Mineralys Therapeutics's earnings have been declining at an average annual rate of -45.1%, while the Biotechs industry saw earnings growing at 36.2% annually.
Key information
-45.14%
Earnings growth rate
13.36%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | n/a |
| Return on equity | -23.78% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Seeking Alpha • May 07
Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move
Summary Mineralys is downgraded from 'Strong Buy' to 'Hold' due to competitive and clinical setbacks. MLYS's lorundrostat NDA was accepted by the FDA with a PDUFA date of December 22, 2026, targeting uncontrolled/resistant hypertension. Failure to meet the primary endpoint in the OSA hypertension subpopulation and AstraZeneca's earlier PDUFA for baxdrostat create significant headwinds. MLYS remains well-capitalized, with cash runway into 2028 and further ATM capacity, but faces execution and competitive risks. Read the full article on Seeking Alpha
New Narrative • Apr 02
Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension and related comorbidities. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 19
Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for patients with uncontrolled and resistant hypertension. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 05
Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled and resistant hypertension and related cardiorenal conditions. What are the underlying business or industry changes driving this perspective?Analysis Article • Jun 14
Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Mar 10
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Summary Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders. The Anti-Hypertensive drugs market worldwide is expected to reach $22.41 billion by 2025. Read the full article on Seeking AlphaAnalysis Article • Feb 20
Is Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Jan 20
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
Summary I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company’s slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects. My main concern with MLYS is its relatively short cash runway. But still, I think it has enough runway to fund its key trials through 2025. Overall, I feel MLYS is a good speculative “Buy” at these levels, especially after a substantial pullback in the shares with promising catalysts lined up in 2025. Read the full article on Seeking AlphaAnalysis Article • Oct 07
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 17
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Summary Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include pivotal phase 2 and 3 trial results in 2025, with significant potential market impact if successful. Despite a solid cash position, further funding may be needed for regulatory stages, making acquisition by a major player a strategic move. Given its potential and current valuation, I recommend a cautious buy for Mineralys at these prices. Read the full article on Seeking AlphaAnalysis Article • Jun 06
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Mar 18
Mineralys Therapeutics: A Story To Keep An Eye On
Summary Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels. The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that has shown promising results in Phase 2 trials for the treatment of uncontrolled hypertension. Mineralys is conducting two additional trials for lorundrostat and is also evaluating its potential for the treatment of hypertension in patients with chronic kidney disease. A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Feb 09
Mineralys: 2nd Half 2024 Hypertension Data Readout
Summary Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN. Results from the phase 3 ADVANCE-HTN study using lorundrostat for the treatment of patients with uncontrolled or resistant hypertension, expected in the 2nd half of 2024. Mineralys is also conducting a phase 2 study for the use of lorundrostat in treating hypertension in Chronic Kidney Disease patients, with results expected in the first half of 2024 or Q1 2025. The global hypertension market is expected to reach $43.18 billion by 2030. Read the full article on Seeking AlphaAnalysis Article • Nov 12
We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Mineralys Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -152 | 53 | 118 |
| 31 Dec 25 | 0 | -155 | 39 | 132 |
| 30 Sep 25 | 0 | -171 | 32 | 152 |
| 30 Jun 25 | 0 | -191 | 28 | 175 |
| 31 Mar 25 | 0 | -189 | 26 | 176 |
| 31 Dec 24 | 0 | -178 | 24 | 169 |
| 30 Sep 24 | 0 | -153 | 21 | 148 |
| 30 Jun 24 | 0 | -120 | 18 | 116 |
| 31 Mar 24 | 0 | -91 | 16 | 89 |
| 31 Dec 23 | 0 | -72 | 14 | 70 |
| 30 Sep 23 | 0 | -57 | 12 | 54 |
| 30 Jun 23 | 0 | -40 | 10 | 38 |
| 31 Mar 23 | 0 | -35 | 7 | 32 |
| 31 Dec 22 | 0 | -30 | 5 | 26 |
| 30 Sep 22 | 0 | -28 | 4 | 25 |
| 31 Dec 21 | 0 | -19 | 2 | 16 |
Quality Earnings: MLYS is currently unprofitable.
Growing Profit Margin: MLYS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MLYS is unprofitable, and losses have increased over the past 5 years at a rate of 45.1% per year.
Accelerating Growth: Unable to compare MLYS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLYS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: MLYS has a negative Return on Equity (-23.78%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 11:03 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mineralys Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Umer Raffat | Evercore ISI |
| Richard J. Law | Goldman Sachs |